The best quarterly since covid took the wind out of our sails -...

The best quarterly since covid took the wind out of our sails - there is a lot to like in this:

• nice jump in cash receipts while US accounts and sales per account was a little down - are we seeing the positive impact of sales outside of the US now? Really important we see traction outside of the US.
• Price rise in place going forward - from the broker report released a couple of months ago, we seem to have a lot of room here with Coopervision being much more expensive from memory
• Cash use, taking out inventory build-up, is going down - excellent. Plus freight cost control in place going forward
• Like the decision to delay any CEO appointment - great to see the board is being careful with our cash, and we just need to grind out our strategy
• Fully randomised clinical trial underway - not much danger here given the effect size seen in the longitudinal study already out there.
• Re-affirmed cash is sufficient to reach approx. breakeven.

Would have liked some specifics on international sales, and an update on the toric lense, but overall very pleasing.